Mechanistically it could be demonstrated that raloxifene decreases atherosclerosis by preventing IL-6-induced phosphorylation of STAT3 and inhibiting the IL-6/GP130 interaction (Tables 3, 4) (95). Here, IL6 is linked to atherosclerosis.